-
公开(公告)号：US20240141070A1
公开(公告)日：2024-05-02
申请号：US17769544
申请日：2020-10-16
发明人： Ting XU , Pilin WANG , Kangping GUO , Yuhao JIN , Ting CHEN , Li GAO , Qingqing ZHANG
CPC分类号： C07K16/468 , A61P31/04 , A61P31/20 , A61P35/00 , C12N15/63 , C07K2317/31 , C07K2317/565
摘要： Provided is an isolated antigen-binding protein, wherein the drug is used for the treatment of tumor, and the isolated antigen-binding protein comprises a PD-L1 binding moiety and an OX40 binding moiety, wherein: the OX40 binding moiety is capable of recognizing and/or binding amino acid residues G70 and/or F71 in a human OX40 extracellular domain; and the PD-L1 binding moiety is capable of recognizing and/or binding amino acid residues I54, Y56, E58, Q66 and/or R113 in an N-terminal IgV domain of human PD-L1. Further provided is a use of the isolated antigen-binding protein in preparing a drug, wherein the drug is used for the treatment of tumors.
-
公开(公告)号：US20230151116A1
公开(公告)日：2023-05-18
申请号：US17914969
申请日：2021-03-26
发明人： Ting XU , Junfang XU , Jing YANG , Jiazhu FANG , Pilin WANG , Ting CHEN
CPC分类号： C07K16/32 , A61P35/00 , C07K2317/31
摘要： The present application provides a method of treating tumor, comprising: administrating a dose of 15 mg/kg to 35 mg/kg of a HER2 bispecific antibody, which comprises a first and a second light chain, a first and a second heavy chain, and variable region of the light chain comprises an amino acid sequence as set forth in any one of SEQ ID NO: 1-6.
-
公开(公告)号：US20230017515A1
公开(公告)日：2023-01-19
申请号：US17782445
申请日：2020-12-03
发明人： Ting XU , Kangping GUO , Junfang XU , Pilin WANG , Yuhao JIN
摘要： The present disclosure provides a use of an immune checkpoint inhibitor in combination with a Her2 inhibitor in the preparation of a medicament for treating tumor in a subject in need thereof, and also provides a pharmaceutical composition comprising an effective amount of said immune checkpoint inhibitor and an effective amount of said Her2 inhibitor, and optionally a pharmaceutically acceptable excipient, as well as a use of the pharmaceutical composition in the preparation of a medicament for treating tumor in a subject in need thereof.
-
公开(公告)号：US20230118053A1
公开(公告)日：2023-04-20
申请号：US17914916
申请日：2021-03-26
发明人： Ting XU , Junfang XU , Pilin WANG , Jing YANG , Jiazhu FANG , Lihong YUN , Yanrong DONG
IPC分类号： A61K39/395 , A61K31/566 , A61P35/00 , A61P35/04 , A61K31/519
摘要： The present application provides a medicinal product comprising: an the HER2 inhibitor or a CDK inhibitor, wherein said CDK inhibitor inhibits CDK4 and/or CDK6. The present application also provides an the HER2 inhibitor for the use of treating tumor in combination with a CDK inhibitor, as well as their use in the preparation of a medicament for treating tumor. The combination in present will significantly enhance tumor inhibiting.
-
公开(公告)号：US20230015590A1
公开(公告)日：2023-01-19
申请号：US17782415
申请日：2020-12-03
发明人： Ting XU , Kangping GUO , Junfang XU , Pilin WANG , Yuhao JIN
摘要： The present disclosure provides a use of a dimer in the preparation of a medicament for treating a tumor in a subject in need thereof, and the dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4. The present disclosure also provides a method for treating a tumor in a subject in need thereof, wherein the subject is resistant to the therapy of an immune checkpoint inhibitor.
-
公开(公告)号：US20240101707A1
公开(公告)日：2024-03-28
申请号：US18454006
申请日：2023-08-22
发明人： Ting XU , Junfang XU , Pilin WANG
IPC分类号： C07K16/32 , A61K31/519 , A61K39/395 , A61P35/00 , C07K16/28 , G01N33/574
CPC分类号： C07K16/32 , A61K31/519 , A61K39/39558 , A61P35/00 , C07K16/2827 , G01N33/57484 , A61K2039/505 , C07K2317/31 , C07K2317/76 , G01N2333/912
摘要： The present application provides a method of treating tumor: administrating a HER2 inhibitor, and said subject comprises an alteration in a protein HER2, CDK12. The present application provides a medicinal product comprising: the HER2 inhibitor and the multiple CDK inhibitor, showing significant inhibition of tumor cell growth.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
